Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
源站原文 ↗Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
源站原文 ↗礼来表示，备受关注的联合减肥疗法在中期试验中促进了体重下降。礼来表示，计划在年底启动将淀粉样蛋白药物eloralintide与tirzepatide联合使用的3期试验。
礼来周三公布中期试验结果，其联合疗法在肥胖合并2型糖尿病患者中减重效果优于单独使用高剂量替尔泊肽。最高剂量联合组平均减重23.3%（约54磅），而15毫克替尔泊肽单药组减重14.8%（34.4磅）。联合疗法还使A1C平均降低最多2.9%。礼来计划2026年底启动三期试验，并调整给药方案以改善耐受性。
以上为 AI 摘要;完整原文请经由源站链接查阅。